Eli Lilly and Company (NYSE: LLY) today announced that new data from across its breast oncology portfolio and pipeline will ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer. Seven-year results from the ...

Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer to be presented as a late-breaking oral ...

Pharmaceutical advancements continue to reshape the landscape of cancer treatment, offering new hope for patients and altering market dynamics. Recent developments in innovative therapies demonstrate ...

Eli Lilly (NYSE:LLY) announced on Wednesday that its FDA-approved antitumor agent Verzenio, as part of a combination regimen, improved overall survival in a late-stage trial for certain patients with ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone ...

(RTTNews) - Eli Lilly and Company (LLY) on Friday reported that two years of adjuvant Verzenio plus endocrine therapy reduced the risk of death by 15.8% compared with endocrine therapy alone in ...